Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis

Molecular Psychiatry volume 21, pages 216–228 (2016)Cite this article

Subjects

Abstract

Peripheral blood brain-derived neurotrophic factor (BDNF) has been proposed as a potential biomarker related to disease activity and neuroprogression in bipolar disorder, speculated to mirror alterations in brain expression of BDNF. The research area is rapidly evolving; however, recent investigations have yielded conflicting results with substantial variation in outcomes, highlighting the need to critically assess the state of current evidence. The aims of the study were to investigate differences in peripheral blood BDNF concentrations between bipolar disorder patients and healthy control subjects and between affective states in bipolar disorder patients, including assessment of the effect of treatment of acute episodes on BDNF levels. A systematic review of English language studies without considering publication status was conducted in PubMed (January 1950–November 2014), Embase (1974–November 2014) and PsycINFO (1806–November 2014), and 35 studies comprising a total of 3798 participants were included in the meta-analysis. The results indicated that crude peripheral blood BDNF levels may be lower in bipolar disorder patients overall (Hedges’ g=−0.28, 95% CI: −0.51 to −0.04, P=0.02) and in serum of manic (g=−0.77, 95% CI: −1.36 to −0.18, P=0.01) and depressed (g=−0.87, 95% CI: −1.42 to −0.32, P=0.002) bipolar disorder patients compared with healthy control subjects. No differences in peripheral BDNF levels were observed between affective states overall. Longer illness duration was associated with higher BDNF levels in bipolar disorder patients. Relatively low study quality, substantial unexplained between-study heterogeneity, potential bias in individual studies and indications of publication bias, was observed and studies were overall underpowered. It could thus not be excluded that identified differences between groups were due to factors not related to bipolar disorder. In conclusion, limitations in the evidence base prompt tempered conclusions regarding the role of peripheral BDNF as a biomarker in bipolar disorder and substantially improving the quality of further research is warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Post RM . Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007; 41: 979–990.

    Article  PubMed  Google Scholar 

  2. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804–817.

    Article  CAS  PubMed  Google Scholar 

  3. Shaltiel G, Chen G, Manji HK . Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2007; 7: 22–26.

    Article  CAS  PubMed  Google Scholar 

  4. Waterhouse EG, Xu B . New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. Mol Cell Neurosci 2009; 42: 81–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Berk M . Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 441–445.

    Article  CAS  PubMed  Google Scholar 

  6. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ . Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553–1561.

    Article  CAS  PubMed  Google Scholar 

  7. Karege F, Schwald M, Cisse M . Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261–264.

    Article  CAS  PubMed  Google Scholar 

  8. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009; 42: 270–276.

    Article  CAS  PubMed  Google Scholar 

  9. Elfving B, Plougmann PH, Muller HK, Mathe AA, Rosenberg R, Wegener G . Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010; 13: 563–572.

    Article  CAS  PubMed  Google Scholar 

  10. Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011; 45: 995–1004.

    Article  PubMed  Google Scholar 

  11. Chou YH, Wang SJ, Lirng JF, Lin CL, Yang KC, Chen CK et al. Impaired cognition in bipolar I disorder: the roles of the serotonin transporter and brain-derived neurotrophic factor. J Affect Disord 2012; 143: 131–137.

    Article  CAS  PubMed  Google Scholar 

  12. Kurita M, Nishino S, Numata Y, Okubo Y, Sato T . The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder i: a clinical naturalistic study. PLoS One 2014; 9: e100634.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lotrich FE, Butters MA, Aizenstein H, Marron MM, Reynolds CF 3rd, Gildengers AG . The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry 2013; 29: 635–644.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Borenstein M, Hedges L, Higgins JPT . Introduction to Meta-Analyses. Wiley: Chicester, NH, USA, 2009.

    Book  Google Scholar 

  15. Lewington S, Bragg F, Clarke R . A review on metaanalysis of biomarkers: promises and pitfalls. Clin Chem 2012; 58: 1192–1204.

    Article  CAS  PubMed  Google Scholar 

  16. Egger M, Schneider M, Davey Smith G . Spurious precision? Meta-analysis of observational studies. BMJ 1998; 316: 140–144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fernandes BS, Berk M, Turck CW, Steiner J, Goncalves CA . Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 2014; 19: 750–751.

    Article  CAS  PubMed  Google Scholar 

  18. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML . BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2014; 174C: 432–440.

    Google Scholar 

  19. Barbosa IG, Rocha NP, Miranda AS, Huguet RB, Bauer ME, Reis HJ et al. Increased BDNF levels in long-term bipolar disorder patients. Rev Bras Psiquiatr 2013; 35: 67–69.

    Article  PubMed  Google Scholar 

  20. Rabie MA, Mohsen M, Ibrahim M, El-Sawy Mahmoud R . Serum level of brain derived neurotrophic factor (BDNF) among patients with bipolar disorder. J Affect Disord 2014; 162: 67–72.

    Article  CAS  PubMed  Google Scholar 

  21. Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS et al. Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naive patients with bipolar II disorder after a twelve-week pharmacological intervention. Acta Psychiatr Scand 2014; 131: 120–128.

    Article  CAS  PubMed  Google Scholar 

  22. Huang T, Larsen KT, Ried-Larsen M, Moller NC, Andersen LB . The effects of physical activity and exercise on brain-derived neurotrophic factor in healthy humans: a review. Scand J Med Sci Sports 2014; 24: 1–10.

    Article  PubMed  Google Scholar 

  23. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011; 36: 228–239.

    Article  CAS  PubMed  Google Scholar 

  24. Moher D, Liberati A, Tetzlaff J, Altman DG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Peters JL, Mengersen KL . Meta-analysis of repeated measures study designs. J Eval Clin Pract 2008; 14: 941–950.

    Article  PubMed  Google Scholar 

  26. Munkholm K, Pedersen BK, Kessing LV, Vinberg M . Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199–211.

    Article  CAS  PubMed  Google Scholar 

  27. Reeves BC, Deeks JJ, Higgins JPT, Wells GA . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). In: Higgins JPT, Green S (ed). The Cochrane Collaboration, 2011www.cochrane-handbook.org.

  28. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses 2009.

  29. Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605.

    Article  PubMed  Google Scholar 

  30. Reeves BC, Deeks JJ, Higgins JPT, Wells GA . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: Higgins JPT, Green S (ed). The Cochrane Collaboration, 2011; www.cochrane-handbook.org.

    Google Scholar 

  31. Grissom RJ, Kim JJ . Effect Sizes for Research: A Broad Practical Approach. Erlbaum: Mahwah, NJ, 2005.

    Google Scholar 

  32. DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.

    Article  CAS  PubMed  Google Scholar 

  33. Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Duval S, Tweedie R . Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455–463.

    Article  CAS  PubMed  Google Scholar 

  36. Borenstein M, Hedges L, Higgins J, Rothstein H . Comprehensive Meta-Analysis. 3rd edn Biostat: Englewood NJ, USA, 2005.

    Google Scholar 

  37. Faul F, Erdfelder E, Lang AG, Buchner A . G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175–191.

    Article  PubMed  Google Scholar 

  38. Barbosa IG, Huguet RB, Mendonca VA, Neves FS, Reis HJ, Bauer ME et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett 2010; 475: 95–98.

    Article  CAS  PubMed  Google Scholar 

  39. Barbosa IG, Rocha NP, Huguet RB, Ferreira RA, Salgado JV, Carvalho LA et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 2012; 137: 151–155.

    Article  CAS  PubMed  Google Scholar 

  40. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Wang TY et al. The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 51: 99–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Cunha ABM, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398: 215–219.

    Article  CAS  PubMed  Google Scholar 

  42. de Oliveira GS, Cereser KM, Fernandes BS, Kauer-Sant'Anna M, Fries GR, Stertz L et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 2009; 43: 1171–1174.

    Article  PubMed  Google Scholar 

  43. de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 2011; 494: 54–56.

    Article  CAS  PubMed  Google Scholar 

  44. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F . Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009; 11: 663–671.

    Article  CAS  PubMed  Google Scholar 

  45. Fernandes BS, Gama CS, Kauer-Sant'Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F . Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 2009; 43: 1200–1204.

    Article  PubMed  Google Scholar 

  46. Grande I, Magalhaes PV, Chendo I, Stertz L, Fries GR, Cereser KM et al. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand 2013; 129: 393–400.

    Article  CAS  PubMed  Google Scholar 

  47. Huang TL, Hung YY, Lee CT, Chen RF . Serum protein levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in bipolar disorder: effects of mood stabilizers. Neuropsychobiology 2012; 65: 65–69.

    Article  CAS  PubMed  Google Scholar 

  48. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PVS, Kauer-Sant'Anna M, Klamt F et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45: 156–161.

    Article  PubMed  Google Scholar 

  49. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447–458.

    Article  CAS  PubMed  Google Scholar 

  50. Kenna HA, Reynolds-May M, Stepanenko A, Ketter TA, Hallmayer J, Rasgon NL . Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. J Affect Disord 2014; 156: 214–218.

    Article  CAS  PubMed  Google Scholar 

  51. Langan C, Doyle K, Kelly J, Emsell L, Skinner R, McDonald C . Serum BDNF levels in euthymic bipolar disorder: preliminary results from the Galway Bipolar Study. Bipolar Disord 2009; 11: 56.

    Google Scholar 

  52. Laske C, Stransky E, Eschweiler GW, Wittorf A, Richartz-Salzburger E, Bartels M et al. Brain-derived neurotrophic factor (BDNF) in serum of patients with mania, major depression and healthy controls. Neurol Psychiatry Brain Res 2005; 12: 25–28.

    Google Scholar 

  53. Li Z, Zhang C, Fan J, Yuan C, Huang J, Chen J et al. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. Br J Psychiatry 2014; 205: 29–35.

    Article  PubMed  Google Scholar 

  54. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007; 61: 142–144.

    Article  CAS  PubMed  Google Scholar 

  55. Mackin P, Gallagher P, Watson S, Young A, Ferrier IN . Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry 2007; 41: 321–326.

    Article  PubMed  Google Scholar 

  56. Monteleone P, Serritella C, Martiadis V, Maj M . Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008; 10: 95–100.

    Article  CAS  PubMed  Google Scholar 

  57. Palomino A, Vallejo-Illarramendi A, Gonzalez-Pinto A, Aldama A, Gonzalez-Gomez C, Mosquera F et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006; 86: 321–322.

    Article  PubMed  Google Scholar 

  58. Panizzutti BS, Wollenhaupt-Aguiar B, Pfaffenseller B, Spanemberg L, Caldieraro MA, Vares EA et al. Evaluation of peripheral biomarkers in bipolar and unipolar depression. Eur Neuropsychopharmacol 2013; 23: S361–S362.

    Article  Google Scholar 

  59. Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med advance online publication, 27 January 2014; 1–10; e-pub ahead of print.

  60. Rybakowski JK, Suwalska A . Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 2010; 13: 617–622.

    Article  CAS  PubMed  Google Scholar 

  61. Sodersten K, Palsson E, Ishima T, Funa K, Landen M, Hashimoto K et al. Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. J Affect Disord 2014; 160: 1–9.

    Article  CAS  PubMed  Google Scholar 

  62. Su SC, Sun MT, Wen MJ, Lin CJ, Chen YC, Hung YJ . Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med 2011; 42: 211–226.

    Article  PubMed  Google Scholar 

  63. Suwalska A, Sobieska M, Rybakowski JK . Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 2010; 62: 229–234.

    Article  CAS  PubMed  Google Scholar 

  64. Tramontina JF, Andreazza AC, Kauer-Sant'anna M, Stertz L, Goi J, Chiarani F et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009; 452: 111–113.

    Article  CAS  PubMed  Google Scholar 

  65. Tunca Z, Ozerdem A, Ceylan D, Yalcin Y, Can G, Resmi H et al. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: the role of lithium. J Affect Disord 2014; 166: 193–200.

    Article  CAS  PubMed  Google Scholar 

  66. Tramontina J, Frey BN, Andreazza AC, Zandona M, Santin A, Kapczinski F . Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry 2007; 12: 230–231.

    Article  CAS  PubMed  Google Scholar 

  67. Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Katsuki A, Hayashi K et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 308–312.

    Article  CAS  PubMed  Google Scholar 

  68. Xiong P, Zeng Y, Wu Q, Han Huang DX, Zainal H, Xu X et al. Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration. J Clin Psychiatry 2014; 75: e794–e801.

    Article  CAS  PubMed  Google Scholar 

  69. Ferensztajn E, Skibinska M, Kaczmarek M, Losy J, Rybakowski JK . Neurobiology and temperament in the offspring of excellent lithium responders. World J Biol Psychiatry 2015; 16: 272–277.

    Article  PubMed  Google Scholar 

  70. Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch RM et al. Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 2000; 5: 510–513.

    Article  CAS  PubMed  Google Scholar 

  71. Hopkins ME, Davis FC, Vantieghem MR, Whalen PJ, Bucci DJ . Differential effects of acute and regular physical exercise on cognition and affect. Neuroscience 2012; 215: 59–68.

    Article  CAS  PubMed  Google Scholar 

  72. Katsuki A, Yoshimura R, Kishi T, Hori H, Umene-Nakano W, Ikenouchi-Sugita A et al. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr 2012; 17: 155–163.

    Article  PubMed  Google Scholar 

  73. Koenigsberg HW, Yuan P, Diaz GA, Guerreri S, Dorantes C, Mayson S et al. Platelet protein kinase C and brain-derived neurotrophic factor levels in borderline personality disorder patients. Psychiatry Res 2012; 199: 92–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009; 70: 1662–1666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009; 43: 247–254.

    Article  PubMed  Google Scholar 

  76. Mesman E, Hillegers MH, Ambree O, Arolt V, Nolen WA, Drexhage HA . Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord 2014; 17: 39–49.

    Article  CAS  PubMed  Google Scholar 

  77. Monteleone P, Fabrazzo M, Martiadis V, Serritella C, Pannuto M, Maj M . Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co-morbid depression, psychopathology and hormonal variables. Psychol Med 2005; 35: 897–905.

    Article  PubMed  Google Scholar 

  78. Monteleone P, Tortorella A, Martiadis V, Serritella C, Fuschino A, Maj M . Opposite changes in the serum brain-derived neurotrophic factor in anorexia nervosa and obesity. Psychosom Med 2004; 66: 744–748.

    Article  CAS  PubMed  Google Scholar 

  79. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN . Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 645–651.

    Article  CAS  PubMed  Google Scholar 

  80. Piccinni A, Marazziti D, Catena M, Domenici L, Del Debbio A, Bianchi C et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008; 105: 279–283.

    Article  CAS  PubMed  Google Scholar 

  81. Pinheiro RT, Pinheiro KA, da Cunha Coelho FM, de Avila Quevedo L, Gazal M, da Silva RA et al. Brain-derived neurotrophic factor levels in women with postpartum affective disorder and suicidality. Neurochem Res 2012; 37: 2229–2234.

    Article  CAS  PubMed  Google Scholar 

  82. Vinberg M, Miskowiak K, Kessing LV . Brain Derived Neurotrophic Factor (BDNF) levels as a possible predictor of psychopathology in healthy twins at high and low risk for affective disorder. Psychoneuroendocrinology 2014; 39: 179–183.

    Article  CAS  PubMed  Google Scholar 

  83. Wang Y, Terao T, Hoaki N, Goto S, Tsuchiyama K, Iwata N et al. Type A behavior pattern and hyperthymic temperament: possible association with bipolar IV disorder. J Affect Disord 2011; 133: 22–28.

    Article  PubMed  Google Scholar 

  84. Yoshimura R, Hori H, Sugita-Ikenouchi A, Umene-Nakano W, Katsuki A, Nakamura J . Serum brain-derived neurotrophic factor levels at 6 months after remission are not associated with subsequent depressive episodes. J Clin Psychopharmacol 2013; 33: 142–143.

    Article  PubMed  Google Scholar 

  85. Aydemir O, Cubukcuo LuZ, Erdin S, Ta C, Onur E, Berk M . Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr 2014; 0: 0.

    Google Scholar 

  86. Barbosa IG, Morato IB, Huguet RB, Rocha FL, Machado-Vieira R, Teixeira AL . Decreased plasma neurotrophin-4/5 levels in bipolar disorder patients in mania. Rev Bras Psiquiatr 2014; 0: 0.

    Google Scholar 

  87. Carlberg L, Scheibelreiter J, Hassler MR, Schloegelhofer M, Schmoeger M, Ludwig B et al. Brain-derived neurotrophic factor (BDNF)-Epigenetic regulation in unipolar and bipolar affective disorder. J Affect Disord 2014; 168: 399–406.

    Article  CAS  PubMed  Google Scholar 

  88. DellOsso B, D'Addario C, Carlotta Palazzo M, Benatti B, Camuri G, Galimberti D et al. Epigenetic modulation of BDNF gene: Differences in DNA methylation between unipolar and bipolar patients. J Affect Disord 2014; 166C: 330–333.

    Article  CAS  Google Scholar 

  89. Fernandes BS, Gama CS, Walz JC, Cereser KM, Fries GR, Colpo G et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J Psychiatr Res 2010; 44: 561–565.

    Article  PubMed  Google Scholar 

  90. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C . Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl Psychiatry 2014; 4: e365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Forlenza OV, Coutinho AM, Aprahamian I, Prando S, Mendes LL, Diniz BS et al. Long-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [F]FDG-PET study. ACS Chem Neurosci 2014; 18: 484–489.

    Article  CAS  Google Scholar 

  92. Frazier TW, Youngstrom EA, Frankel BA, Zunta-Soares GB, Sanches M, Escamilla M et al. Candidate gene associations with mood disorder, cognitive vulnerability, and fronto-limbic volumes. Brain Behav 2014; 4: 418–430.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Giglio LM, Andreazza AC, Andersen M, Cereser KM, Walz JC, Sterz L et al. Sleep in bipolar patients. Sleep Breath 2009; 13: 169–173.

    Article  PubMed  Google Scholar 

  94. Hosang GM, Uher R, Keers R, Cohen-Woods S, Craig I, Korszun A et al. Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. J Affect Disord 2010; 125: 345–349.

    Article  CAS  PubMed  Google Scholar 

  95. Huang CC, Chang YH, Lee SY, Chen SL, Chen SH, Chu CH et al. The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 2012; 159b: 501–507.

    Article  CAS  PubMed  Google Scholar 

  96. Karege F, Schwald M, El Kouaissi R . Drug-induced decrease of protein kinase a activity reveals alteration in BDNF expression of bipolar affective disorder. Neuropsychopharmacology 2004; 29: 805–812.

    Article  CAS  PubMed  Google Scholar 

  97. Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F et al. Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. Eur Neuropsychopharmacol 2002; 12: 269–272.

    Article  CAS  PubMed  Google Scholar 

  98. Matsuo K, Walss-Bass C, Nery FG, Nicoletti MA, Hatch JP, Frey BN et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 2009; 34: 1904–1913.

    Article  CAS  PubMed  Google Scholar 

  99. Moreira L, Neves FS, Romano-Silva MA, Malloy-Diniz LF, Correa H . BDNF and episodic memory in patients with bipolar disorder. Rev Bras Psiquiatr 2011; 33: 96–97.

    Article  PubMed  Google Scholar 

  100. Pfaffenseller B, Wollenhaupt-Aguiar B, Fries GR, Colpo GD, Burque RK, Bristot G et al. Impaired endoplasmic reticulum stress response in bipolar disorder: cellular evidence of illness progression. Int J Neuropsychopharmacol 2014; 17: 1453–1463.

    Article  CAS  PubMed  Google Scholar 

  101. Ray MT, Shannon Weickert C, Webster MJ . Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl Psychiatry 2014; 4: e389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Rybakowski JK, Borkowska A, Skibinska M, Hauser J . Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin card sorting test in bipolar mood disorder [5]. Mol Psychiatry 2006; 11: 122–124.

    Article  CAS  PubMed  Google Scholar 

  103. Schroeter ML, Steiner J . Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009; 14: 235–237.

    Article  CAS  PubMed  Google Scholar 

  104. Walz JC, Andreazza AC, Frey BN, Cacilhas AA, Cereser KM, Cunha AB et al. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci Lett 2007; 415: 87–89.

    Article  CAS  PubMed  Google Scholar 

  105. Wang Z, Zhang C, Huang J, Yuan C, Hong W, Chen J et al. MiRNA-206 and BDNF genes interacted in bipolar I disorder. J Affect Disord 2014; 162: 116–119.

    Article  CAS  PubMed  Google Scholar 

  106. Zarate CA Jr., Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54–60.

    Article  CAS  PubMed  Google Scholar 

  107. Andreazza AC, Young LT . The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int J Neuropsychopharmacol 2014; 17: 1039–1052.

    Article  CAS  PubMed  Google Scholar 

  108. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC . Inflammatory mediators of cognitive impairment in bipolar disorder. J Psychiatr Res 2014; 56: 18–27.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Colom F, Vieta E . Sudden glory revisited: Cognitive contents of hypomania. Psychother Psychosom 2007; 76: 278–288.

    Article  PubMed  Google Scholar 

  110. Gass P, Hellweg R . Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders? Int J Neuropsychopharmacol 2010; 13: 1–4.

    Article  CAS  PubMed  Google Scholar 

  111. Gonzalez-Castro TB, Nicolini H, Lanzagorta N, Lopez-Narvaez L, Genis A, Pool Garcia S et al. The role of brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism in bipolar disorder: a case-control study, comorbidities, and meta-analysis of 16,786 subjects. Bipolar Disord 2014; 17: 27–38.

    Article  CAS  PubMed  Google Scholar 

  112. Kapczinski F, Dias VV, Frey BN, Kauer-Sant'Anna M . Brain-derived neurotrophic factor in bipolar disorder: beyond trait and state: comment on 'Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders'. Bipolar Disord 2009; 11: 221–222.

    Article  PubMed  Google Scholar 

  113. Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1366–1371.

    Article  CAS  PubMed  Google Scholar 

  114. Lardner AL . Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders. Nutr Neurosci 2014; 17: 145–155.

    Article  CAS  PubMed  Google Scholar 

  115. Leeds PR, Yu F, Wang Z, Chiu CT, Zhang Y, Leng Y et al. A new avenue for lithium: intervention in traumatic brain injury. ACS Chem Neurosci 2014; 18: 422–433.

    Article  CAS  Google Scholar 

  116. Mackin P, Gallagher P, Neumeister A, Manji HK . Brain-derived neurotrophic factor in patients with remitted depression [7] (multiple letters). Am J Psychiatry 2005; 162: 2399–2400.

    Article  PubMed  Google Scholar 

  117. Pae CU . Comments on ‘Low plasma BDNF is associated with suicidal behavior in major depression’ by Y.K. Kim et al. Progress in Neuropsychopharmacology and Biological Psychiatry 2006 Aug 9; [Epub ahead of print]. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 578–579, author reply 580-571.

    Article  CAS  PubMed  Google Scholar 

  118. Rizzo LB, Costa LG, Mansur RB, Swardfager W, Belangero SI, Grassi-Oliveira R et al. The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research. Neurosci Biobehav Rev 2014; 42: 157–169.

    Article  PubMed  Google Scholar 

  119. Teixeira AL, Barbosa IG, Diniz BS, Kummer A . Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med 2010; 4: 871–887.

    Article  CAS  PubMed  Google Scholar 

  120. Grande I, Magalhaes PV, Chendo I, Stertz L, Panizutti B, Colpo GD et al. Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatr Scand 2014; 129: 437–444.

    Article  CAS  PubMed  Google Scholar 

  121. Kauer-Sant'Anna M, Tramontina J, Andreazza AC, Cereser K, da Costa S, Santin A et al. Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord 2007; 9 Suppl 1: 128–135.

    Article  PubMed  Google Scholar 

  122. Yatham LN, Kapczinski F, Andreazza AC, Trevor Young L, Lam RW, Kauer-Sant'anna M . Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 137–139.

    Article  CAS  PubMed  Google Scholar 

  123. Chen SL, Lee SY, Chang YH, Chen PS, Lee IH, Wang TY et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol 2014; 24: 1753–1759.

    Article  CAS  PubMed  Google Scholar 

  124. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A . Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol 2013; 28: 87–90.

    Article  CAS  PubMed  Google Scholar 

  125. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F . Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007; 420: 45–48.

    Article  CAS  PubMed  Google Scholar 

  126. Grande I, Kapczinski F, Stertz L, Colpo GD, Kunz M, Cereser KM et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res 2012; 46: 1511–1514.

    Article  PubMed  Google Scholar 

  127. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PVS, Kauer-Sant'Anna M, Klamt F et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010; 15: 784–786.

    Article  CAS  PubMed  Google Scholar 

  128. Kapczinski F, Frey BN, Andreazza AC, Kauer-Sant'Anna M, Cunha AB, Post RM . Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 2008; 30: 243–245.

    Article  PubMed  Google Scholar 

  129. Frank E, Nimgaonkar VL, Phillips ML, Kupfer DJ . All the world/'s a (clinical) stage: rethinking bipolar disorder from a longitudinal perspective. Mol Psychiatry 2015; 20: 23–31.

    Article  CAS  PubMed  Google Scholar 

  130. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry advance online publication, 30 September 2014; e-pub ahead of print.

  131. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM . Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014; 19: 791–800.

    Article  CAS  PubMed  Google Scholar 

  132. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013; 14: 365–376.

    Article  CAS  PubMed  Google Scholar 

  133. Wang Z, Li Z, Gao K, Fang Y . Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis. BMC Psychiatry 2014; 14: 5.

    Article  Google Scholar 

  134. Daruy-Filho L, Brietzke E, Lafer B, Grassi-Oliveira R . Childhood maltreatment and clinical outcomes of bipolar disorder. Acta Psychiatr Scand 2011; 124: 427–434.

    Article  CAS  PubMed  Google Scholar 

  135. Sala R, Goldstein BI, Wang S, Blanco C . Childhood maltreatment and the course of bipolar disorders among adults: epidemiologic evidence of dose-response effects. J Affect Disord 2014; 165: 74–80.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Bortoluzzi A, Salum GA, Blaya C, Silveira PP, Grassi-Oliveira R, da Rosa ED et al. Mineralocorticoid receptor genotype moderates the association between physical neglect and serum BDNF. J Psychiatr Res 2014; 59: 8–13.

    Article  PubMed  Google Scholar 

  137. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26: 115–123.

    Article  CAS  PubMed  Google Scholar 

  138. Cho HC, Kim J, Kim S, Son YH, Lee N, Jung SH . The concentrations of serum, plasma and platelet BDNF are all increased by treadmill VO(2)max performance in healthy college men. Neurosci Lett 2012; 519: 78–83.

    Article  CAS  PubMed  Google Scholar 

  139. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G . Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57: 1068–1072.

    Article  CAS  PubMed  Google Scholar 

  140. Higgins JP, Thompson SG . Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663–1682.

    Article  PubMed  Google Scholar 

  141. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011; 14: 347–353.

    Article  CAS  PubMed  Google Scholar 

  142. Lanz TA, Bove SE, Pilsmaker CD, Mariga A, Drummond EM, Cadelina GW et al. Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma. Biomarkers 2012; 17: 524–531.

    Article  CAS  PubMed  Google Scholar 

  143. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M . Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry 2015; 20: 152–153.

    Article  CAS  PubMed  Google Scholar 

  144. Cooke MS, Barregard L, Mistry V, Potdar N, Rozalski R, Gackowski D et al. Interlaboratory comparison of methodologies for the measurement of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine. Biomarkers 2009; 14: 103–110.

    Article  CAS  PubMed  Google Scholar 

  145. Munkholm K, Brauner JV, Kessing LV, Vinberg M . Cytokines in bipolar disorder vs healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47: 1119–1133.

    Article  PubMed  Google Scholar 

  146. Kato T . Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 2008; 44: 92–102.

    Article  CAS  PubMed  Google Scholar 

  147. Brown NC, Andreazza AC, Young LT . An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014; 218: 61–68.

    Article  CAS  PubMed  Google Scholar 

  148. Goldstein BI, Young LT . Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep 2013; 15: 425.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Mesman E, Hillegers MH, Ambree O, Arolt V, Nolen WA, Drexhage HA . Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord 2015; 17: 39–49.

    Article  CAS  PubMed  Google Scholar 

  150. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR . Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. N Engl J Med 2002; 347: 1557–1565.

    Article  CAS  PubMed  Google Scholar 

  151. Koenig W, Lowel H, Baumert J, Meisinger C . C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349–1353.

    Article  PubMed  Google Scholar 

  152. Altman DG, Riley RD . Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2005; 2: 466–472.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Lundbeck Foundation, Denmark (R34-A3696), the Danish Council for Independent Research|Medical Sciences (09–073972), the Augustinus Foundation (12–3075) and Overlæge dr. med. Einar Geert-Jørgensen og hustru Ellen Geert-Jørgensens research foundation (13517-001). We thank the authors of included papers, in particular all of the authors supplying unpublished data for the present study.

Author information

Authors and Affiliations

  1. Psychiatric Center Copenhagen, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

    K Munkholm, M Vinberg & L V Kessing

Authors
  1. K Munkholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Vinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L V Kessing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Munkholm.

Ethics declarations

Competing interests

LVK has within the preceding 3 years been a consultant for Lundbeck and AstraZeneca. MV has been a consultant for Lundbeck, AstraZeneca, Eli Lilly and Servier. KM declares no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Molecular Psychiatry website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Munkholm, K., Vinberg, M. & Kessing, L. Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. Mol Psychiatry 21, 216–228 (2016). https://doi.org/10.1038/mp.2015.54

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2015.54

This article is cited by

Search

Advanced search

Quick links